StockData
Mineralys Therapeutics, Inc. logo

Mineralys Therapeutics, Inc. (MLYS) stock

MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$14.48−0.05 (-0.34%)

Close on Nov 17, 2026Market cap $1.28BP/E –Yield –

Earnings

Mineralys Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.64
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Mineralys Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close––-$0.64Release
Q2 FY2026ended Jun 30, 2026Aug 11, 2026after the close––-$2.85Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close–––Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 10, 2025after the close–––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close––-$0.66Release
Q1 FY2025ended Mar 31, 2025May 12, 2025after the close––-$0.79Release
Q4 FY2024ended Dec 31, 2024Feb 12, 2025before the open–––Release
Q3 FY2024ended Sep 30, 2024Nov 12, 2024before the open–––Release
Q2 FY2024ended Jun 30, 2024Aug 13, 2024after the close––-$0.83Release
Q1 FY2024ended Mar 31, 2024May 9, 2024before the open––-$0.70Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Mineralys Therapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Mineralys Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Mineralys Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. News
  10. News
  11. Results
  12. Update
  13. Results
  14. Update
  15. News

See a number that looks wrong?